ArticleBMC infectious diseases2026
Effectiveness and tolerability of low dose clindamycin for treatment of prosthetic joint infections, a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClindamycin is a potential drug for treating prosthetic joint infections, but pharmacokinetic monitoring shows that coadministration with rifampicin significantly reduces clindamycin concentrations. This study aimed to describe the real-world effectiveness and tolerability of clindamycin given alone or in combination with rifampicin or other antibiotics for treatment of PJI.
methodsThis single-centre, retrospective cohort study, included patients treated for PJI from 2010 to 2022. PJI was defined according to a modified version of the 2011 Musculoskeletal Infection Society (MSIS) definition that was used clinically during the study period. Patients treated with a clindamycin-based therapy (used when first-line drugs were unsuitable) were included. Data were extracted manually from electronic records. Cure required no clinical or microbiological signs of recurrence of the same bacteria after 24 months of follow-up. Factors affecting treatment outcome were assessed using logistic regression analyses.
resultsThe two-year treatment success after clindamycin monotherapy (n = 46) and combination therapy (n = 62) at a typical dose of 300 mg three times daily was 82% (95% confidence interval [CI] 75-90%, n = 89/108). Two-year clindamycin treatment success following DAIR (n = 46), one stage exchange (n = 23) and two stage exchange (n = 32) were 72% (95% CI 58-85%), 91% (95% CI 79-100) and 94% (95% CI 85-100), respectively. Overall treatment success was 80% (95% CI 67-93%, n = 40) for patients receiving clindamycin/rifampicin. Staphylococcus aureus was independently associated with lower treatment success in a multivariable logistic regression OR 0.17 CI (0.05-0.64, p = 0.008). Side-effects were more frequent in patients receiving clindamycin + rifampicin (39%) compared to clindamycin monotherapy (10%) p = 0.002).
conclusionsClindamycin (300 mg three times daily), administered as monotherapy or in combination with other antibiotics including rifampicin, appeared to be an effective and well-tolerated treatment for PJI. However, these regimens may be less effective in infections caused by S. aureus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.